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Abstract Progelatinase A is a matrix metalloproteinase in- 
volved in the turnover of extracellular matrix (ECM). We report 
that the ECM produced by bovine corneal endothelial (BCE) cells 
contains progelatinase A free of tissue inhibitor of metallopro- 
teinase (TIMP2). The matrix-bound progelatinase A can be acti- 
vated by APMA to generate a 62 kDa and a 45 kDa species with 
enzymatic activity and is inhibited by TIMP2. The bound proge- 
latinase can be released after treatment of the ECM with gelati- 
nase B. These studies suggest hat the ECM can function as a 
reservoir for progelatinase A which may be readily available for 
cells in processes uch as metastasis, angiogenesis, inflammation 
and wound heating. 
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1. Introduction 
The ECM plays an active and complex role in regulating the 
morphogenesis of cells that contact it, influencing their devel- 
opment, migration, proliferation and metabolic functions [1,2]. 
It is now evident hat the ECM provides a storage depot for 
growth factors (e.g. bFGF,  TGFfl) [3,4], enzymes (e.g. tPA, 
uPA) [5,6], enzyme inhibitors (e.g. PAl l)  [7] and plasma pro- 
teins (e.g. plasminogen) [8]. Some of the biological effects of the 
ECM can be attributed to the combined action of structural 
adhesive macromolecules and ECM-immobilized molecules 
that are thereby protected and stabilized [9,10]. 
The 72-kDa progelatinase A (MMP-2, 72-kDa type IV col- 
lagenase) and the 92-kDa progelatinase B (MMP-9, 92-kDa 
type IV collagenase) are two matrix metalloproteinases thought 
to play a role in the degradation and remodeling of ECM 
during development, metastasis formation and angiogenesis 
[11]. Like other members of the MMP family, the gelatinases 
are secreted as inactive zymogens requiring activation to attain 
enzymatic activity [11] and are specifically inhibited by the 
tissue inhibitors of metalloproteinases (TIMPs) [11]. The phys- 
iological mechanisms of activation of the progelatinases are not 
completely understood but may involve the action of other 
proteases including MMPs. For example, a recently described 
membrane-associated matrix metalloproteinase has been 
shown to activate progelatinase A [12]. The localization and 
binding of progelatinase A to the surface of certain tumor cells 
may facilitate its activation by the membrane MMP [13,14]. The 
present study was designed to analyse whether the gelatinases 
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may also bind to the ECM. These proteinases may bind to the 
collagenous components of ECM through their fibronectin-like 
gelatin binding domain which is only present in the gelatinases 
[11 ]. We report on the presence of progelatinase A in the suben- 
dothelial ECM produced by cultured bovine corneal endothe- 
lial (BCE) cells. These cells produce an underlying extracellular 
matrix (ECM) that closely resembles the subendothelial base- 
ment membrane deposited in vivo in its morphological ppear- 
ance and molecular composition. 
2. Materials and methods 
2.1. Recombinant enzymes and inhibitors 
Human recombinant progelatinase A, progelatinase B, TIMP-1 and 
TIMP-2 were all expressed in mammalian cells using a recombinant 
vaccinia virus expression system (Vac/T7)as previously described [15- 
17]. Proenzymes were purified from serum-free medium by gelatin- 
affinity chromatography [18]. TIMP-2 was purified by affinity chroma- 
tography using a mouse mAb against TIMP-2, as described previously 
[16,17]. TIMP-1 was purified from the media of infected cells using a 
lentil ectin-Sepharose 4B (Sigma) [19]. The concentration f the puri- 
fied enzymes and TIMPs was determined by amino acid analysis. 
2.2. Cells 
Cultures of bovine corneal endothelial (BCE) cells were established 
from steer eyes as previously described [20]. Stock cultures were main- 
tained in DMEM (1 g/1 glucose) supplemented with 10% heat-inac- 
tivated newborn calf serum (NCS), 5% heat inactivated FCS, 50 U/ml 
penicillin, and 50 gtg/ml streptomycin at 37°C in a 10% CO2 humidified 
incubator. Partially purified brain-derived bFGF (100 ng/ml) was 
added every other day during the phase of active cell growth. 
2.3. ECM-coated ishes, ECM extracts and serum-free conditioned 
media 
BCE cells were dissociated from stock cultures (second to fifth pas- 
sage) with trypsin/EDTA and plated into culture dishes. After reaching 
confluence, BCE cells were maintained for additional 7 days in com- 
plete medium containing 5% dextran T-40 and without addition of 
bFGF. The complete medium was then aspirated, the cells washed (4×) 
with PBS and 0.25 ml of serum-free DMEM were added to each dish 
(35 mm) to obtain conditioned media. Twenty-four hours afterwards 
the serum-free medium was collected, centrifuged toremove cell debris 
and stored at -20°C until used. The subendothelial ECM was exposed 
by dissolving (5 min, room temperature) the cell layer with sterile PBS 
containing 0.5% Triton X-100 and 20 mM NH4OH, followed by four 
washes in PBS. The ECM remained intact, free of cellular debris and 
firmly attached to the entire area of the tissue culture dish [5,21,22]. 
ECM extracts for zymography were prepared by scrapping the ECM- 
coated culture dishes (35 mm) with the aid of a rubber policeman i 250 
/11 of Laemmli sample gel buffer (10% SDS, 30% glycerol, 0.25 M 
Tris-HCl, pH 6.8, 0.1% Bromophenol b ue) [23] diluted 1:3 with water. 
2.4. Zymography and enzymatic assays 
Gelatin SDS-substrate g ls (zymograms) were prepared as previously 
described [24]. Briefly, 1 mg/ml of gelatin was incorporated into the 
standard Laemmli SDS-10% polyacrylamide g ls. Aliquots (25 ,ul) of 
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either solubilized ECM, serum-free conditioned media or purified en- 
zymes were subjected to gelatin-SDS-PAGE without heating or reduc- 
tion. After electrophoresis, the gels were washed twice with 2.5% Triton 
X-100 with gentle shaking for 30 rain at room temperature. The gels 
were then rinsed with distilled water and incubated in assay bufffer (50 
mM Tris-HCl, pH 7.5, 5 mM CaCI2, 0.02% NAN3) at 37°C for 24 h. 
For reverse zymography, the zymograms were incubated (37°C, 12 h) 
with assay buffer containing APMA-activated recombinant gelatinase 
B (1/2g/ml). The gels were then stained for 1 h with 2% Coomassie blue 
in R-250, 30% isopropyl alcohol and 10% acetic acid, followed by 
destaining in 30% isopropyl alcohol and 10% acetic acid. 
Gelatinolytic activity was assayed using [3H]gelatin as substrate as 
described previously [25]. The ECM of 35 mm culture dishes was 
scraped with a rubber policeman into 50 mM Tris pH 7.5, 5 mM CaCI2 
buffer (250/21/dish). Aliquots (25 /21) were incubated with 0.5 mM 
APMA (30 min, 37°C) prior to assay. Pure recombinant APMA-acti- 
vated gelatinase A (10 ng/reaction) was assayed in parallel. Samples 
were incubated for 3 h at 37°C with 100/2g [3H]gelatin (50,000 cprn/mg) 
in a total volume of 250/21 of 50 mM Tris-HCl buffer pH 7.6, 5 mM 
CaCI 2 and 0.01% Brij 35. The reaction was stopped by the addition of 
ice-cold trichloroacetie acid to a final concentration of 12% (w/v) and 
samples were incubated at 4°C for 1 h. After centrifugation at 
15,000 × g for 15 min, the radioactivity in 100/21 of supernatant was 
determined by liquid scintillation spectrometry. 
2.5. Immunoblot analysis 
Samples of purified enzymes, TIMPs, ECM extracts and conditioned 
medium were dissolved in SDS-PAGE sample buffer and electrophor- 
esed on 10% SDS-PAGE under educing conditions followed by trans- 
fer onto a nitrocellulose membrane. After blocking with 3% bovine 
serum albumin and 3% non-fat dry milk in 50 mM Tris-HC1 pH 7.5, 
the blots were incubated with either anti-gelatinase A (CA-801), anti- 
gelatinase B (CA-809) or anti-TIMP-2 (CA-101) mouse monoclonal 
antibodies (5 pg/ml), or with anti TIMP-1 rabbit polyclonal antibodies 
(1:500 dilution) diluted in 50 mM Tris-HCl pH 7.5, 150 mM NaCI, 
0.1% Tween 20. Immunoreactivity was visualized by successive incuba- 
tions with alkaline phosphatase-conjugated goat anti-mouse (or anti- 
rabbit for TIMP-1) IgG and color developing substrates. The prepara- 
tion of mAb against human progelatinase A, progelatinase B and 
TIMP-2 were previously described [26,27]. The rabbit polyclonal anti- 
serum against human TIMP-1 was kindly provided by Dr. Chua 
(Wayne State University). 
2.6. Release of ECM-bound gelatinase A 
ECM-coated wells (16 mm) were incubated at 37°C for various time 
periods with either bacterial heparinase I (0.05 U/ml), human placental 
heparanase (0.6 mg/ml), chondroitinase ABC (0.2 U/ml), gelatinase B 
(5/2g/ml) with or without 0.5 mM APMA or with 0.5 mM APMA 
alone. The incubation was carried out in 50 mM Tris pH 7.5, 50 mM 
NaCI, 1 mM CaC12 (250 pl/well), except in the case of placental hepar- 
anase where 10 mM citrate-phosphate buffer pH 6.0 with 50 mM NaCI 
and 1 mM CaC12 was used. At the end of the incubation, the super- 
natants were collected, centrifuged, and 25/21 analyzed by zymography 
as described above. 
3. Results 
3.1. The subendothelial ECM of BCE cells contains 
progelatinase A
Extracts of BCE-ECM and conditioned media were analyzed 
by gelatin-zymography (Fig. 1A) and immunoblotting (Fig. 1B) 
for the presence of gelatinases. Purified human recombinant 
progelatinase A and B were used as positive controls. As shown 
in Fig. 1A and B, both assays demonstrated that the BCE-ECM 
extract and the conditioned media contained only progelatinase 
A. In contrast, progelatinase B could not be detected by these 
assays in both the ECM and the conditioned media of BCE cells. 
The ECM and conditioned medium were examined for the 
presence of TIMP-1 and TIMP-2 by immunoblot analysis using 
a mAb against human TIMP-2 and a rabbit polyclonal anti- 
m 
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Fig. 1. Zymography and immunoblot of ECM and conditioned media 
of BCE cells. ECM extracts (ECM) and serum-free conditioned media 
(CM) of BCE cells were prepared as described in section 2and analyzed 
by gelatin zymography (A) and immunoblot (B). Gelatin zymogram: 
25/21 of serum-free conditioned medium (CM); 25/21 solubilized ECM; 
20 ng human recombinant progelatinase A (GEL A); 20 ng human 
recombinant progelatinase B (GEL B). Immunoblot: 50/21 of serum- 
free conditioned medium (CM); 50/21 solubilized ECM; 100 ng human 
recombinant progelatinase A (GEL A). For immunoblots, amples 
were subjected to SDS-PAGE under reducing conditions followed by 
transfer onto nitrocellulose paper. The blots were incubated with an 
mAb against human progelatinase A (5/2g/ml) followed by alkaline 
phosphatase conjugated goat anti-mouse IgG. 
body against human TIMP-1. Purified human recombinant 
TIMP-1 and TIMP-2 were used as positive controls. It was 
found that BCE cells do not secrete detectable TIMPs into the 
ECM and conditioned medium (not shown). To rule out the 
possibility that the lack of detection of TIMPs was due to a lack 
of antibody cross-reactivity, the ECM and conditioned medium 
were also analyzed by reverse zymography. This technique al- 
lows the detection of MMP inhibitors. Neither a 30-kDa nor 
a 21-kDa inhibitory bands corresponding to T IMP- I  and 
TIMP-2, respectively, could be detected by this method, indi- 
cating that cultured BCE cells under this conditions do not 
secrete detectable TIMP-1 and TIMP-2. 
Since the 72 kDa enzyme present in ECM extract was in the 
latent form, we examined its activation with APMA. For this 
purpose, ECM was incubated (30 min, 37°C) with 0.5 mM 
APMA followed by zymography. As shown in Fig. 2A, APMA 
treatment of the BCE-ECM resulted in the conversion ofproge- 
latinase A into a major active form of 62 kDa and an additional 
minor active species of 45 kDa. A faint 3~35 kDa active form 
was also detected. Both the 45- and the 35-kDa species were 
recognized by a mAb to progelatinase A indicating that these 
fragment were derived from progelatinase A (not shown). Ad- 
dition of TIMP-2 (0.5 pg/35 mm dish) to the ECM prior to the 
addition of APMA,  inhibited the activation of the ECM-bound 
progelatinase A, as indicated by a strong reduction of the 62- 
kDa form and disappearance of the smaller active fragments. 
This effect is probably due to the ability of TIMP-2 to form a 
complex with the latent gelatinase A in solubilized ECM. These 
results are consistent with previous studies with purified en- 
zyme [16,17] showing that the complex cannot be fully activated 
by APMA. Since the ECM-bound gelatinase appears to be free 
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Fig. 2. Activation of ECM-bound progelatinase A and effect of TIMP- 
2. BCE-ECM from a 35 mm culture dish was scraped with a rubber 
policeman into 250/zl of 50 mM Tris pH 7.5, 5 mM CaClz buffer. 
Scraped ECM was incubated (30 min, 37°C) with either buffer alone 
(ECM), buffer with 0.5 mM APMA (ECM + APMA) or with buffer 
containing 0.5/2g of human recombinant TIMP-2 for 10 min prior to 
the addition of APMA (ECM + APMA + TIMP-2). The samples (25 
/tl) were then analyzed by gelatin zymography (A) and for activity 
against gelatin (B) as described in section 2. This experiment was re- 
peated 3 times with similar results. Each data point represents the 
average of triplicate dishes and the standard eviation did not exceed 
15%. 
of TIMP-2, the pattern of APMA activation shown in Fig. 2A 
is consistent with studies using purified TIMP-2-free gelatinase 
A. 
APMA treatment of the BCE-ECM generated enzymatic 
activity against soluble [3H]gelatin which was inhibited by the 
addition of TIMP-2, suggesting that the gelatinase can be acti- 
vated while bound to the ECM (Fig. 2B). However, the contri- 
bution to this activity by other MMPs which may be present 
in the ECM, such as stromelysin, cannot be ruled out since 
these enzymes can also be inhibited by TIMP-2. 
3.2. Release of ECM-bound progelatinase A
Since progelatinase A associates with the ECM, we investi- 
gated its release using various ECM-degrading enzymes. Spon- 
taneous release of progelatinase A into the incubation buffer 
alone was small (Fig. 3). APMA treatment of the ECM caused 
release of activated gelatinase A, as indicated by the appearance 
of the 62- and the 45-kDa forms in the incubation medium. 
Incubation of the ECM with APMA-activated gelatinase B
caused a release of the 72-kDa proenzyme form of gelatinase 
A, together with the two (62 and 45 kDa) active forms. The 
appearance of the active gelatinase A forms after treatment 
with gelatinase B may be due to the effect of the APMA as seen 
after treatment of the ECM with APMA alone. Since the latent 
ECM-bound gelatinase A was not released into the buffer after 
treatment of ECM with APMA alone, this result suggests that 
the release of the latent gelatinase A after treatment of ECM 
with the APMA-activated gelatinase B may be a consequence 
of the action of the gelatinase B. The higher molecular weight 
bands seen correspond to the added gelatinase B. These results 
suggest that the ECM component involved in binding of proge- 
latinase A is sensitive to the proteolytic action of the gelati- 
nases. When ECM-coated dishes were incubated with either 
placental heparanase (0.6 mg/ml), bacterial heparinase I (0.05 
U/ml) or with chondroitinase ABC (0.2 U/ml), none of these 
enzymes released progelatinase A from its association with the 
63 
BCE-ECM as the gelatinolytic activity released was similar to 
that released in buffer alone. Thus, degradation of heparan 
sulfate, dermatan sulfate and chondroitin sulfate does not pro- 
mote the release of the ECM bound progelatinase A.
4. Discussion 
In the present study we show that the ECM of BCE cells 
contains progelatinase A. The ECM bound enzyme was found 
in the latent form and free of TIMPs as determined by im- 
munoblot analysis and reverse zymography. These findings are 
in agreement with a previous [6] study showing that matrigel, 
a reconstituted basement membrane, contains progelatinase A 
and B but undetectable TIMP activity in reverse zymography. 
Here we have shown that ECM-bound progelatinase A was 
activated by APMA generating enzymatic activity and forming 
the 62-kDa active species and an additional minor active frag- 
ment of 45 kDa, a pattern of activation consistent with a pro- 
enzyme form free of TIMP-2 as previously reported [17,28]. 
Preincubation of the ECM with TIMP-2 inhibited the activa- 
tion of the ECM-bound enzyme in agreement with previous 
studies using soluble enzyme and inhibitor [17]. We have re- 
cently reported that formation of the 45-kDa species involves 
an autolytic leavage of both the N-terminal profragment and 
the C-terminal domain (Fridman et al., in preparation). Since 
the C terminal end is required for the efficient inhibition of 
gelatinase A by TIMP-2, enzyme species like the 45-kDa form, 
if present in vivo, may escape the regulatory control of TIMP-2 
[16,29]. Furthermore, we have found that both the 62- and the 
45-kDa species can activate progelatinase B. Thus, formation 
of these species in the ECM may play a role in the degradation 
of ECM by directly degrading matrix proteins, or indirectly by 
activating other MMPs. An interesting observation of this 
study was the specific release of ECM-bound progelatinase by 
treatment of the ECM with gelatinase B which can be brought 
to the matrix by migratory cells such as polymorphonuclear 
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Fig. 3. Release of ECM-bound progelatinase A. ECM-coated wells (16 
mm) were incubated (1 h or 5 h, 37°C) with 250/21/well of either buffer 
alone (50 mM Tris pH 7.5, 50 mM NaCI, 2 mM CaCI2) (BUF); or buffer 
containing 0.5 mM APMA (APMA) or human recombinant gelatinase 
B (5/2g/ml) with 0.5 mM APMA (GEL B APMA). Aliquots (25/21) of 
the supernatant were centrifuged (5 min, 15,000 × g) and assayed by 
zymography. Control of gelatinase B (5/2g/ml) with 0.5 mM APMA 
was assayed in parallel (CONT GEL B APMA). 
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leukocytes, macrophages and tumor cells. Other ECM-degrad- 
ing enzymes, in contrast, failed to release progelatinase A from 
the matrix to the supematant. This suggests that the ECM 
component/s involved in the association of progelatinase A 
with the ECM may be susceptible to the proteolytic attack of 
gelatinase B. Although the precise substrate specificity of gelati- 
nase B is not known, it is somewhat different from that of 
gelatinase A [30,31]. The binding of progelatinase A to the 
ECM may be mediated by its fibronectin-like gelatin binding 
domain [18,30] to the collagen component of the ECM. 
The presence of progelatinase A in the ECM may be com- 
pared to that of active tissue-type and urokinase-type lasmin- 
ogen activators [5]. ECM-bound plasminogen, for example, 
was found to be a better substrate for tissue plasminogen acti- 
vator (t-PA) than soluble plasminogen and it was protected 
from inhibition by plasmin inhibitor [8]. Likewise, ECM-bound 
thrombin was protected from inactivation by its physiological 
inhibitor anti-thrombin III [32]. However the significance of the 
binding of progelatinase A to the ECM remains to be deter- 
mined. Since progelatinase A is mainly produced by stromal 
cells surrounding tumors [33-35], the proenzyme may be se- 
questered by the ECM, awaiting activation by the appropriate 
signal. Recently a membrane bound matrix metalloproteinase 
which induced specific activation of progelatinase A was iden- 
tified on the surface of invasive tumor cells [12]. This enzyme 
may trigger invasion, tumor cell proliferation and angiogenesis 
by activating stromal and ECM-bound progelatinase A at the 
invasive dge of tumor cell nests. 
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